Revolution Medicines, Inc.
RVMDW· Nasdaq
RVMDWRevolution Medicines, Inc.
Filed Mar 2, 2021 · 10-K · 61 days after period end · 0001564590-21-010276
| Metric | Q4 2020 | Q4 2019 |
|---|---|---|
| Revenue | $8.75M | $12.09M |
| Net Income | -$34.20M | -$14.60M |
| EPS Diluted | -$0.52 | -$6.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 2, 2021 · 61 d after period end
